Timber Creek Capital Management LLC Purchases Shares of 16,113 Becton, Dickinson and Company (NYSE:BDX)

Timber Creek Capital Management LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,113 shares of the medical instruments supplier's stock, valued at approximately $3,691,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Vanguard Group Inc. raised its holdings in Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after purchasing an additional 184,288 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after buying an additional 3,219,317 shares during the period. Geode Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock valued at $1,437,161,000 after purchasing an additional 66,024 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Becton, Dickinson and Company by 15.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after acquiring an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 31.4% in the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after buying an additional 1,057,879 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president owned 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Down 0.6%

Shares of NYSE:BDX traded down $1.11 during mid-day trading on Friday, hitting $176.16. 1,057,606 shares of the company traded hands, compared to its average volume of 2,058,031. The firm's 50 day simple moving average is $174.52 and its 200 day simple moving average is $208.14. The firm has a market cap of $50.49 billion, a P/E ratio of 33.62, a PEG ratio of 1.33 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.17 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 79.39%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BDX shares. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Finally, The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.